Wave Life Sciences Ltd. Insider Trading

WVE

Last 12 months

Insiders sold $16.2M and bought nothing on the open market.

98% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Dec 2023.

Net open-market

−$16.2M

0 buys · 19 sales

Under a 10b5-1 plan

98%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Dec 2023

Dec 11, 2023

Get an email when WVE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 12	Adrian Rawcliffe Director	Sold10b5-1 plan	12,700	$5.29	67K	100%	Form 4
Aug 11	Heidi L Wagner Director	Sold10b5-1 plan	7,000	$6.01	42K	13%	Form 4
Aug 11	Ken Takanashi Director	Sold10b5-1 plan	3,864	$6.01	23K	<0.1%	Form 4
Aug 11	Aik Na Tan Director	Sold10b5-1 plan	432	$6.01	3K	1.7%	Form 4
Mar 26 – 30	RA Capital Management, L.p. Large holder	Bought 4 parts	8,772,496	$6.23 average	$54.6M	48%	Form 4
Feb 26	Chris Francis See Remarks	Sold10b5-1 plan 2 parts	33,194	$15.05 average	500K	35%	Form 4
Feb 9	Kyle Moran Chief Financial Officer	SoldNo plan	3,588	$13.45	48K	2.6%	Form 4
Feb 9	Paul Bolno President and CEO	SoldNo plan	10,480	$13.45	141K	3.7%	Form 4
Feb 9	Chris Francis See Remarks	SoldNo plan	1,883	$13.45	25K	3.0%	Form 4
Feb 9	Chandra Vargeese See Remarks	SoldNo plan	3,228	$13.45	43K	0.8%	Form 4
Jan 2	Chris Francis See Remarks	Sold10b5-1 plan 2 parts	9,375	$16.03 average	150K	27%	Form 4
Dec 11, 2025	GSK Plc Large holder	Bought	1,470,000	$19.00	$27.9M	8.8%	Form 4
Dec 8, 2025 – Dec 9, 2025	Kyle Moran Chief Financial Officer	Sold10b5-1 plan 6 parts	260,036	$15.78 average	$4.1M	74%	Form 4
Dec 8, 2025	Adrian Rawcliffe Director	Sold10b5-1 plan	42,000	$15.00	630K	77%	Form 4
Dec 8, 2025	Heidi L Wagner Director	Sold10b5-1 plan 2 parts	14,000	$13.50 average	189K	24%	Form 4
Dec 8, 2025	Christian O Henry Director	Sold10b5-1 plan 4 parts	93,445	$14.65 average	$1.37M	88%	Form 4
Dec 8, 2025	Aik Na Tan Director	Sold10b5-1 plan 8 parts	134,218	$13.58 average	$1.82M	84%	Form 4
Dec 8, 2025	Gregory L. Verdine Director	Sold10b5-1 plan 2 parts	20,000	$13.47 average	269K	6.8%	Form 4
Dec 8, 2025	Chris Francis See Remarks	Sold10b5-1 plan 9 parts	441,031	$14.58 average	$6.43M	95%	Form 4
Dec 8, 2025	Mark Corrigan Director	Sold10b5-1 plan 2 parts	16,115	$13.49 average	217K	36%	Form 4
Nov 13, 2025	RA Capital Management, L.p. Large holder	Bought	1,000	$6.69	7K	<0.1%	Form 4
Nov 13, 2025	Adrian Rawcliffe Director	Sold10b5-1 plan	16,115	$6.79	109K	56%	Form 4
Aug 22, 2025	Gregory L. Verdine Director	Sold10b5-1 plan	10,000	$10.00	100K	3.4%	Form 4
Aug 22, 2025	Paul Bolno President and CEO	Sold10b5-1 plan	217,351	$10.10	$2.2M	64%	Form 4
Aug 15, 2025	Aik Na Tan Director	Sold10b5-1 plan	21,000	$9.25	194K	34%	Form 4
Aug 13, 2025	Christian O Henry Director	Sold10b5-1 plan	9,670	$8.81	85K	25%	Form 4
Aug 5, 2025	Ken Takanashi Director	Sold10b5-1 plan	4,872	$8.75	43K	<0.1%	Form 4
Aug 5, 2025	Aik Na Tan Director	Sold10b5-1 plan	1,127	$8.75	10K	7.0%	Form 4
Jun 13, 2025	Gregory L. Verdine Director	Sold10b5-1 plan	30,000	$6.95	209K	9.6%	Form 4
Mar 20, 2025	Christian O Henry Director	Sold10b5-1 plan	10,500	$9.77	103K	39%	Form 4
Mar 7, 2025	Paul Bolno President and CEO	Sold10b5-1 plan	169,025	$9.57	$1.62M	33%	Form 4
Nov 25, 2024	Paul Bolno President and CEO	Sold10b5-1 plan	50,000	$15.00	750K	19%	Form 4
Nov 15, 2024	Paul Bolno President and CEO	Sold10b5-1 plan	51,234	$14.32	734K	19%	Form 4
Nov 8, 2024	Chris Francis See Remarks	Sold10b5-1 plan	36,000	$16.00	576K	100%	Form 4

Aug 1210b5-1 plan
Adrian Rawcliffe
Director · sold 12,700 at $5.29
67K
100% of stake
Aug 1110b5-1 plan
Heidi L Wagner
Director · sold 7,000 at $6.01
42K
13% of stake
Aug 1110b5-1 plan
Ken Takanashi
Director · sold 3,864 at $6.01
23K
<0.1% of stake
Aug 1110b5-1 plan
Aik Na Tan
Director · sold 432 at $6.01
3K
1.7% of stake
Mar 26 – 30
RA Capital Management, L.p.
Large holder · bought 8,772,496 at avg $6.23
$54.6M
48% of stake
Feb 2610b5-1 plan
Chris Francis
See Remarks · sold 33,194 at avg $15.05
500K
35% of stake
Feb 9No plan
Kyle Moran
Chief Financial Officer · sold 3,588 at $13.45
48K
2.6% of stake
Feb 9No plan
Paul Bolno
President and CEO · sold 10,480 at $13.45
141K
3.7% of stake
Feb 9No plan
Chris Francis
See Remarks · sold 1,883 at $13.45
25K
3.0% of stake
Feb 9No plan
Chandra Vargeese
See Remarks · sold 3,228 at $13.45
43K
0.8% of stake
Jan 210b5-1 plan
Chris Francis
See Remarks · sold 9,375 at avg $16.03
150K
27% of stake
Dec 11, 2025
GSK Plc
Large holder · bought 1,470,000 at $19.00
$27.9M
8.8% of stake
Dec 8, 2025 – Dec 9, 202510b5-1 plan
Kyle Moran
Chief Financial Officer · sold 260,036 at avg $15.78
$4.1M
74% of stake
Dec 8, 202510b5-1 plan
Adrian Rawcliffe
Director · sold 42,000 at $15.00
630K
77% of stake
Dec 8, 202510b5-1 plan
Heidi L Wagner
Director · sold 14,000 at avg $13.50
189K
24% of stake
Dec 8, 202510b5-1 plan
Christian O Henry
Director · sold 93,445 at avg $14.65
$1.37M
88% of stake
Dec 8, 202510b5-1 plan
Aik Na Tan
Director · sold 134,218 at avg $13.58
$1.82M
84% of stake
Dec 8, 202510b5-1 plan
Gregory L. Verdine
Director · sold 20,000 at avg $13.47
269K
6.8% of stake
Dec 8, 202510b5-1 plan
Chris Francis
See Remarks · sold 441,031 at avg $14.58
$6.43M
95% of stake
Dec 8, 202510b5-1 plan
Mark Corrigan
Director · sold 16,115 at avg $13.49
217K
36% of stake
Nov 13, 2025
RA Capital Management, L.p.
Large holder · bought 1,000 at $6.69
7K
<0.1% of stake
Nov 13, 202510b5-1 plan
Adrian Rawcliffe
Director · sold 16,115 at $6.79
109K
56% of stake
Aug 22, 202510b5-1 plan
Gregory L. Verdine
Director · sold 10,000 at $10.00
100K
3.4% of stake
Aug 22, 202510b5-1 plan
Paul Bolno
President and CEO · sold 217,351 at $10.10
$2.2M
64% of stake
Aug 15, 202510b5-1 plan
Aik Na Tan
Director · sold 21,000 at $9.25
194K
34% of stake
Aug 13, 202510b5-1 plan
Christian O Henry
Director · sold 9,670 at $8.81
85K
25% of stake
Aug 5, 202510b5-1 plan
Ken Takanashi
Director · sold 4,872 at $8.75
43K
<0.1% of stake
Aug 5, 202510b5-1 plan
Aik Na Tan
Director · sold 1,127 at $8.75
10K
7.0% of stake
Jun 13, 202510b5-1 plan
Gregory L. Verdine
Director · sold 30,000 at $6.95
209K
9.6% of stake
Mar 20, 202510b5-1 plan
Christian O Henry
Director · sold 10,500 at $9.77
103K
39% of stake
Mar 7, 202510b5-1 plan
Paul Bolno
President and CEO · sold 169,025 at $9.57
$1.62M
33% of stake
Nov 25, 202410b5-1 plan
Paul Bolno
President and CEO · sold 50,000 at $15.00
750K
19% of stake
Nov 15, 202410b5-1 plan
Paul Bolno
President and CEO · sold 51,234 at $14.32
734K
19% of stake
Nov 8, 202410b5-1 plan
Chris Francis
See Remarks · sold 36,000 at $16.00
576K
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch WVE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with WVE

CompareIntrinsic value

VRDNViridian Therapeutics Inc.

$29.06+15.53%40

RMTIRockwell Medical, Inc.

$8.05-0.49%37

FBIOFortress Biotech Inc.

$1.97+1.55%59

DERMJourney Medical Corp

$4.73+1.94%25

OMEROmeros Corporation

$18.18-0.49%27

CYTKCytokinetics, Incorporated

$63.60+2.07%10

ASMBAssembly Biosciences Inc.

$19.87-0.25%19

ABCLAbCellera Biologics Inc.

$12.28+0.82%10

Held by ETFs

WVE is in 14 US ETFs. The largest of them, with WVE's weight in each:

Spot a number that looks wrong? Check it in WVE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing WVE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.